Jin X, Deng Q, Ye S, Liu S, Fu Y, Liu Y, Wu G, Ouyang G, Wu T.
Theranostics. 2024 May 13;14(7):3014-3028. doi: 10.7150/thno.94207. eCollection 2024.
PMID:38773979
Role of CDKN2C Fluorescence In Situ Hybridization in the Management of Medullary Thyroid Carcinoma.
El Naofal M, Kim A, Yon HY, Baity M, Ming Z, Bui-Griffith J, Tang Z, Robinson M, Grubbs EG, Cote GJ, Hu P.
Ann Clin Lab Sci. 2017 Sep;47(5):523-528.
PMID:29066476
High Diagnostic Accuracy of Epigenetic Imprinting Biomarkers in Thyroid Nodules.
Xu H, Zhang Y, Wu H, Zhou N, Li X, Pineda JP, Zhu Y, Fu H, Ying M, Yang S, Bao J, Yang L, Zhang B, Guo L, Sun L, Lu F, Wang H, Huang Y, Zhu T, Wang X, Wei Q, Sheng C, Qu S, Lv Z, Xu D, Li Q, Dong Y, Qin J, Cheng T, Xing M.
J Clin Oncol. 2023 Feb 20;41(6):1296-1306. doi: 10.1200/JCO.22.00232. Epub 2022 Nov 15.
PMID:36378996
Detection of NTRK1/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing.
Lee YC, Chen JY, Huang CJ, Chen HS, Yang AH, Hang JF.